Abbott Laboratories (ABT)

Health Care · Health Care Equipment · US stock · S&P 500 component

$102.51 ▲ +2.00 (1.99%)

At close 22 Oct 2026 · USD · Volume 10,649,514

Compare with BSX

Interactive chart Research report Forecast ranges Pro workspace SEC filings Historical data

Fair valueFair

$92 −10.5% to fair value

$46fair band $78–$111$138

Day's range

$99.95 – $102.90

52-week range

$81.97 – $132.03

About Abbott Laboratories

Abbott Laboratories is a diversified health care company whose products cover medical devices, diagnostics, nutrition and established pharmaceuticals. Its range includes diabetes monitoring sensors, heart and neuromodulation devices, laboratory and point-of-care testing systems, and nutritional products such as Similac and Ensure. Customers include hospitals, clinicians, laboratories, retailers and consumers in markets around the world.

Revenue comes from a broad mix of device, diagnostic, nutrition and pharmaceutical products. It totals $45.1 billion over the last twelve months, with growth of 0.5% a year across the last three years. The operating margin is 17.1%, and the business earns a profit of 8% on the capital invested in it. Abbott carries net debt of 3.5 times EBITDA, and the dividend yield is 2.5%. On the site's X-Ray Score it receives 41 out of 100.

Price chart

Interactive chart Historical data & CSV

52-wk range $81.97 – $132.03Volume 10,649,514Daily, split-adjusted

Vitals

Market cap$179.1B

52-week range$81.97 – $132.03

Volume (last day)10,649,514

P/E (TTM)28.6

EBIT / EV yield3.7%

Free-cash-flow yield4.1%

Dividend yield2.5%

Revenue (TTM)$45.1B

Net income (TTM)$6.3B

Operating margin17.1%

Return on capital7.5%

Debt incl. leases$34.0B

Cash & securities$7.3B

Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.

Fair value estimate

$92middle half of models $86 – $104

Fair −10.5% to fair value

Average of the 15 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is High, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.

Price $103

Undervalued < $78Fair $78 – $111Overvalued > $111

P/E multiple

$103

P/B multiple

$125

P/S multiple

$107

EV/EBITDA multiple

$94

EV/EBIT multiple

$106

EV/revenue multiple

$103

10-year DCF, EBITDA exit

$86

5-year DCF, EBITDA exit

$96

10-year DCF, revenue exit

$86

5-year DCF, revenue exit

$96

10-year DCF, growth exit

$42

5-year DCF, growth exit

$44

Dividend discount, stable

$86

Dividend discount, multi-stage

$134

Earnings power value

$67

Growth the price implies

22.9%/yr

A model estimate, not a price target or recommendation. Inputs: risk-free 5.13%, equity risk premium 4.30% (Damodaran). How it works.

What this means

Weak business, fairly priced

The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.

Before you invest · decision checklist

I understand how this company makes money Business quality is average or better 42 The price is not above fair value $92 fair value Debt looks manageable 3.5× EBITDA Revenue has been growing 0.5% a year Profits are backed by cash There are no red flags none raised I know what share of my savings this would be

Ticked boxes are filled in from our data; the rest are yours to answer.

The five-lens scan

Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.

Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data

Valuation Weak

35/100

Expensive against its sector on earnings and cash flow.

See the numbers →

EBIT / EV yield3.7%

Free-cash-flow yield4.1%

Fair value vs price0.9×

Growth Weak

37/100

Growing slower than most of its sector.

See the numbers →

Revenue growth (3y)0.5%

EPS growth (3y)-1.6%

Growth consistency100%

Profitability Weak

42/100

Earns lower returns on its capital than most peers.

See the numbers →

Return on invested capital7.5%

Operating margin17.1%

Gross profitability23.0%

Financial health Weak

42/100

Balance sheet is more stretched than most peers.

See the numbers →

Piotroski F-Score6 / 9

Net debt / EBITDA3.5×

Interest cover14.4×

Dividends Fair

59/100

Dividend is typical for its sector.

See the numbers →

Dividend yield2.5%

Dividends vs free cash flow60%

Dividend growth7.5%

Quarterly results: last 6 quarters

+7.2%

Dec '24

+4.0%

Mar '25

+7.4%

Jun '25

+6.9%

Sep '25

+4.4%

Dec '25

+7.8%

Mar '26

Revenue against the same quarter a year earlier. Latest quarter revenue $11.2B, diluted EPS $0.61.

Compare with peers

DXCM Dexcom Inc78 PODD Insulet Corp72 RMD Resmed Inc70 BSX Boston Scientific Corp67

Other Health Care Equipment companies by X-Ray Score.

SWOT analysis: Abbott Laboratories

Strengthsinside the company

Operating profit covers interest 14x, so debt costs are a small drag.

Weaknessesinside the company

No clear weakness in the figures we track.

Opportunitiesvaluation and setting

Revenue growth picked up to 5.7% last year from 0.5% a year over three years.

Threatsvaluation and setting

Valuation uncertainty is high: the models give widely different values, so the fair value range is wide.

Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.

Compare ABT with peers and sector

Medians of 15 Health Care Equipment peers and of 59 Health Care stocks in our universe. Largest peers (X-Ray Score): ISRG 62, MDT 57, SYK 56, BSX 67, BDX 47, EW 55.

Metric	ABT	Peers	Sector
X-Ray Score (out of 100)	41	57	49
Valuation	35	60	55
Growth	37	74	48
Profitability	42	55	51
Financial health	42	64	48
Dividends	59	35	50

Sector leaders: highest X-Ray Score in Health Care

ABT ranks #46 of 60 in Health Care and #14 of 16 in Health Care Equipment by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.

Company	X-Ray Score
#1 INCY Incyte Corp	80
#2 DXCM Dexcom Inc	78
#3 PODD Insulet Corp	72
#4 RMD Resmed Inc	70
#5 ZTS Zoetis Inc.	69
…
#46 ABT Abbott Laboratories (this stock)	41

Metric	ABT	Peers	Sector
P/E ratio	28.5x	31.2x	28.0x
PEG ratio	–	1.24	2.35
Price / book	3.4x	3.2x	4.0x
Price / sales	4.0x	3.8x	3.6x
EV / EBITDA	26.8x	17.4x	17.5x
Price / free cash flow	24.3x	24.9x	22.3x
Dividend yield	2.5%	1.0%	1.0%
Gap to our fair value	−10.5%	+3.6%	−1.0%

Metric	ABT	Peers	Sector
Price change, 1 month	−0.5%	+8.3%	+7.6%
Price change, 3 months	+2.6%	+11.7%	+14.9%
Price change, 6 months	+13.3%	+6.8%	+22.3%
Price change, 1 year	−17.9%	−4.0%	+21.9%

Metric	ABT	Peers	Sector
Market value	$179.1B	$37.0B	$49.2B
Revenue (last 12 months)	$45.1B	$8.5B	$14.3B
EBITDA (last 12 months)	$7.7B	$2.1B	$2.7B
Net income (last 12 months)	$6.3B	$1,000M	$1.4B
Free cash flow (last 12 months)	$7.4B	$1.5B	$2.1B

Metric	ABT	Peers	Sector
Revenue growth, last year	+5.7%	+9.9%	+7.2%
Revenue growth, 3 years a year	+0.5%	+9.4%	+5.6%
EPS growth, 3 years a year	−1.6%	+18.7%	+5.5%
Free cash flow growth, 3 years a year	−1.8%	+35.0%	+4.5%
Dividend growth	+7.5%	+1.8%	+4.1%

Metric	ABT	Peers	Sector
Gross margin	56.3%	63.7%	65.0%
EBITDA margin	17.1%	26.5%	21.2%
Operating margin	17.1%	18.9%	15.8%
Net margin	13.9%	13.3%	10.0%
Return on invested capital	7.5%	10.7%	12.5%
Return on equity	12.1%	14.7%	13.7%

Metric	ABT	Peers	Sector
Net debt / EBITDA	3.5x	1.6x	2.0x
Interest cover	14.4x	18.8x	9.3x
Current ratio	1.4x	1.9x	1.5x
Piotroski F-score (0 to 9)	6	7	6

Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.

Factor ratings for ABT

Each factor is rated by where ABT stands among the 60 Health Care stocks in our universe.

Rating against the sector

Goodthe top third of these stocks

Averagethe middle third of these stocks

Badthe bottom third of these stocks

"Beats" is the share of those stocks it is ahead of.

Against its own history

The last columns set today's figure against the company's own median of its last five financial years:

▲ Betterbetter than its usual level

▼ Worseworse than its usual level

≈ In linewithin its usual range

For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.

In total: 0 Good · 18 Average · 5 Bad of 23 Growth: 0 · 1 · 2 Profitability: 0 · 4 · 1 Financial strength: 0 · 3 · 1 Valuation: 0 · 4 · 1 Cash flow: 0 · 4 · 0 Efficiency: 0 · 2 · 0

Factor	ABT	Rating	Sector median	Own 5-year median	Against own history
Growth
Revenue growth, 3 years a year	+0.5%	Bad beats 18%	+5.5%	–	–
Revenue growth, last year	+5.7%	Average beats 36%	+7.1%	+4.6%	≈ In line
EPS growth, 3 years a year	−1.6%	Bad beats 27%	+5.0%	–	–
Profitability
Gross margin	56.3%	Average beats 37%	65.0%	56.1%	≈ In line
Operating margin	17.1%	Average beats 53%	16.4%	18.2%	≈ In line
Net margin	13.9%	Average beats 58%	11.1%	15.9%	▼ Worse
Return on invested capital	7.5%	Bad beats 26%	12.2%	–	–
Return on equity	12.1%	Average beats 42%	13.7%	18.9%	▼ Worse
Financial strength
Net debt / EBITDA	3.5x	Bad beats 23%	2.0x	0.9x	▼ Worse
Interest cover	14.4x	Average beats 55%	9.4x	15.0x	≈ In line
Current ratio	1.39	Average beats 44%	1.52	1.64	▼ Worse
Piotroski F-score	6 / 9	Average beats 43%	6 / 9	–	–
Valuation
P/E ratio	28.5x	Average beats 48%	28.2x	33.6x	▲ Better
Price / book	3.4x	Average beats 54%	3.7x	5.0x	▲ Better
Price / sales	4.0x	Average beats 46%	3.7x	4.8x	▲ Better
EV / EBITDA	26.8x	Bad beats 29%	17.6x	29.9x	▲ Better
Free cash flow yield	4.1%	Average beats 41%	4.4%	3.4%	≈ In line
Cash flow
Free cash flow margin	16.3%	Average beats 50%	16.3%	16.7%	≈ In line
Cash from operations / net income	1.51	Average beats 46%	1.61	1.38	≈ In line
Free cash flow growth, 3 years a year	−1.8%	Average beats 36%	+4.3%	–	–
Accruals (lower is better)	−2.9%	Average beats 37%	−3.9%	–	–
Efficiency
Inventory turnover	2.8x	Average beats 48%	2.9x	3.0x	≈ In line
Days sales outstanding	66 days	Average beats 40%	62 days	60 days	▼ Worse

These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings). A dash in the history columns means fewer than three usable years.

Fundamentals checklist

● 1 Good · ● 9 Average · ● 6 Bad

Cash quality

Earnings backed by cashAverage

Free-cash-flow yieldAverage

Risk models

Altman Z''Average

Piotroski F-ScoreAverage

Growth

EPS growth (3y)Bad

Free-cash-flow growth (3y)Average

Revenue growth (3y)Bad

Growth consistencyGood

Balance sheet

Current ratioAverage

Net debt / EBITDABad

Interest coverAverage

Valuation

Fair value vs priceBad

EBIT / EV yieldAverage

Profitability

Return on invested capitalBad

Operating marginAverage

Gross profitabilityBad

Each check is graded against the company's sector, not a fixed number. Checklist score 38/100.

Financials

	FY21	FY22	FY23	FY24	FY25
Revenue	$43.1B	$43.7B	$40.1B	$42.0B	$44.3B
Operating income	$8.4B	$8.4B	$6.5B	$6.8B	$8.1B
Net income	$7.1B	$6.9B	$5.7B	$13.4B	$6.5B
Operating cash flow	$10.5B	$9.6B	$7.3B	$8.6B	$9.6B
Operating margin	19.6%	19.2%	16.2%	16.3%	18.2%
Free cash flow	$8.6B	$7.8B	$5.1B	$6.4B	$7.4B
Diluted EPS	$3.94	$3.91	$3.26	$7.64	$3.72

Fiscal years, from SEC filings.

Technical summary

Daily

Bullish

9 bullish · 4 neutral · 3 bearish

Weekly

Bearish

4 bullish · 1 neutral · 7 bearish

Monthly

Strongly bearish

1 bullish · 1 neutral · 6 bearish

Moving averages (daily)

SMA 10	102.4	Bullish
EMA 10	102.0	Bullish
SMA 20	100.5	Bullish
EMA 20	101.8	Bullish
SMA 50	104.8	Bearish
EMA 50	102.2	Bullish
SMA 100	100.2	Bullish
EMA 100	101.7	Bullish
SMA 200	101.0	Bullish
EMA 200	103.8	Bearish

Oscillators (daily)

RSI (14)	51.73	Neutral
MACD (12, 26)	-0.04	Bearish
Momentum (12)	5.07	Bullish
Stochastic %K (14)	60.59	Neutral
Williams %R (14)	-39.41	Neutral
CCI (20)	43.45	Neutral

Pivot points (classic, last session)

97.72

98.84

100.7

Pivot

101.8

103.6

104.7

106.6

Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Dividends

Paid, last 12 months

2.52 USD

Yield on today's price

2.46%

Frequency

Quarterly

Next ex-dividend date

Not announced

Ex-dividend date	Amount per share
15 Oct 2026	0.6300
15 Jul 2026	0.6300
15 Apr 2026	0.6300
15 Jan 2026	0.6300
15 Oct 2025	0.5900
15 Jul 2025	0.5900
15 Apr 2025	0.5900
15 Jan 2025	0.5900
15 Oct 2024	0.5500
15 Jul 2024	0.5500
12 Apr 2024	0.5500
11 Jan 2024	0.5500

Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.

ETFs that hold ABT

ETF	Share of the fund
IHI iShares U.S. Medical Devices	16.93%
IYH iShares U.S. Healthcare	3.02%
SCHD Schwab U.S. Dividend Equity	2.96%
XLV Health Care Select Sector SPDR	2.75%
FHLC Fidelity MSCI Health Care Index	2.66%
VHT Vanguard Health Care	2.35%
HDV iShares Core High Dividend	2.29%
QLTY GMO U.S. Quality	2.29%

The eight funds with the largest weight in ABT among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.